Insider Analysis: Kantar Health On Optimizing Indian Cancer Patient Assistance Programs For Maximum Impact
This article was originally published in PharmAsia News
With a rapidly rising cancer burden but the high costs of new targeted therapies remaining out of reach for many, India has seen the increasing adoption of company-backed patient assistance programs, or PAPs, to support access to effective treatments. But what is the best approach? Kantar Health’s Gauri Pathak and Neesha Suvarna look at the issues.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.